Confirmed Delta Variant COVID-19 Infection at A Single Centre Tertiary Hospital: A Case Series

Sally Aman Nasution, Muhadi Muhadi, Eric Daniel Tenda


SARS-CoV-2 continues to mutate with the emergence of new variants. Variant B.1.617.2 (Delta) is a variant of concern with evidence of increased transmission, more severe disease, decreased effectiveness of treatment or vaccines, or failure of diagnostic detection. In this article, we report on the clinical and biological picture of the first confirmed delta variant COVID-19 infection in Indonesia. From May 31 to June 17, we identified ten cases with confirmed delta variant COVID-19 infection admitted to a tertiary academic hospital in Jakarta. All subjects that have been vaccinated presented with mild-moderate disease. Most patients present with initial respiratory complaints, without radiological abnormalities on chest x-ray examination, and an increase in C-reactive protein. Seven out of ten patients have been vaccinated; the three patients who had not been vaccinated experienced severe COVID-19 symptoms, two of whom died. Due to the increased transmission of this variant, we recommend vaccination, wearing a mask, and social distancing to reduce the impact of infection with delta variant B.1,617.2.


COVID-19; delta variant; vaccination status; variant of concern


World Health Organization. WHO Coronavirus (COVID-19) Dashboard 2021 [Available from:

Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409-24.

Del Rio C, Malani PN, Omer SB. Confronting the Delta Variant of SARS-CoV-2, Summer 2021. JAMA. 2021.

Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions 2021 [Available from:

Chia PY, Ong SWX, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. MedRXiV. 2021.

Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.

Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. 2020;382(18):1708-20.

Fathi N, Rezaei N. Lymphopenia in COVID-19: Therapeutic opportunities. Cell Biol Int. 2020;44(9):1792-7.

Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2(8):1069-76.

Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622-9.

Mlcochova P, Kemp S, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant emergence, replication and sensitivity to neutralising antibodies. Nature. 2021:2021.05.08.443253.

Vacharathit V, Aiewsakun P, Manopwisedjaroen S, et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis. 2021;21(10):1352-4.

Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461-2.

Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. NEJM. 2021;384(15):1412-23.

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.